Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Virginia Araiza

Pediatric Endocrinology Houston, TX Medical Doctor

NPI 1164757712 CMS profile 143383

3701 W Alabama St Ste 350, Houston, TX 77027

Open in the dashboard

General payments

$151,272

565 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Virginia Araiza of Houston, TX is reported in the CMS Open Payments database as having received $151,272 across 565 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 96th percentile of Pediatric Endocrinology profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $15,432 85
2024 General $40,158 121
2023 General $5,588 45
2022 General $9,594 59
2021 General $8,902 50
2020 General $15,688 53
2019 General $55,910 152

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Virginia Araiza
  • Pediatric Endocrinology median
  • Middle half of Pediatric Endocrinology
  • National median

In program year 2025, general payments to Virginia Araiza were reported at $15,432. Among 971 Pediatric Endocrinology profiles paid that year, the median was $293 and the middle half received between $106 and $1,640.

Show as a table
Year Virginia Araiza Pediatric Endocrinology median Middle half National median
2019 $55,910 $196 $68–$845 $163
2020 $15,688 $124 $37–$722 $114
2021 $8,902 $134 $35–$691 $132
2022 $9,594 $177 $47–$726 $149
2023 $5,588 $236 $75–$887 $160
2024 $40,158 $259 $91–$979 $164
2025 $15,432 $293 $106–$1,640 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Alexion Pharmaceuticals, Inc. $145,901 316 payments
  2. AbbVie, Inc. $1,403 73 payments
  3. Novo Nordisk Inc $729 42 payments
  4. Abbott Laboratories $510 13 payments
  5. Tandem Diabetes Care, Inc. $336 12 payments
  6. Insulet Corporation $326 17 payments
  7. Dexcom, Inc. $276 15 payments
  8. Sanofi-Aventis U.S. LLC $236 11 payments
  9. Xeris Pharmaceuticals, Inc. $234 11 payments
  10. Ascendis Pharma, Inc. $162 7 payments
  11. Other $1,158 48 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $110,925 71 payments
  2. Travel and Lodging $27,740 151 payments
  3. Food and Beverage $10,100 341 payments
  4. Consulting Fee $2,500 1 payment
  5. Education $7 1 payment
Products named General payments · program years 2019–2025
  1. STRENSIQ Rare Disease $23,779 58 payments
  2. Strensiq Endocrinology $4,765 10 payments
  3. LUPRON DEPOT Endocrinology $1,076 56 payments
  4. Sogroya $405 22 payments
  5. FreeStyle Libre $349 11 payments
  6. t:slim X2 Insulin Pump with Control-IQ $292 10 payments
  7. LUPRON DEPOT Endocrinology $194 6 payments
  8. Omnipod $178 8 payments
  9. TZIELD $176 8 payments
  10. Norditropin $169 11 payments
  11. Other $2,567 124 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

565 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatric Endocrinology in Texas

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record